All In Biotech

Drug Trial Radar · NCT06761898

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

A Phase 1, Open-label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Food on the Pharmacokinetics of a Single Oral Dose of BGB-43395 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Jan 14, 2025

Primary completion

May 20, 2025

Study completion May 20, 2025

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jan 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.

Conditions

  • Healthy Volunteers

Interventions

  • BGB-43395Drug

    Administered orally as solid dispersion tablet or salt tablet

  • BGB-43395Drug

    Administered orally as solid dispersion tablet or salt tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and 2: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  2. Part 1 and 2: Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  3. Part 1 and 2: Maximum Observed Concentration (Cmax)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  4. Part 1 and 2: Time of the Maximum Observed Concentration (Tmax)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  5. Part 1 and 2: Apparent Terminal Elimination Half-life (t1/2)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  6. Part 1 and 2: Apparent Total Clearance (CL/F)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
  7. Part 1 and 2: Apparent Volume of Distribution (Vz/F)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Cru, Daytone Beach

    Daytona Beach, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.